206 related articles for article (PubMed ID: 18670644)
1. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Bhattacharya A; Tóth K; Durrani FA; Cao S; Slocum HK; Chintala S; Rustum YM
Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
[TBL] [Abstract][Full Text] [Related]
2. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Bhattacharya A; Tóth K; Mazurchuk R; Spernyak JA; Slocum HK; Pendyala L; Azrak R; Cao S; Durrani FA; Rustum YM
Clin Cancer Res; 2004 Dec; 10(23):8005-17. PubMed ID: 15585636
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
Azrak RG; Yu J; Pendyala L; Smith PF; Cao S; Li X; Shannon WD; Durrani FA; McLeod HL; Rustum YM
Mol Cancer Ther; 2005 May; 4(5):843-54. PubMed ID: 15897249
[TBL] [Abstract][Full Text] [Related]
4. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
[TBL] [Abstract][Full Text] [Related]
5. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Cao S; Durrani FA; Rustum YM
Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
Yin MB; Li ZR; Tóth K; Cao S; Durrani FA; Hapke G; Bhattacharya A; Azrak RG; Frank C; Rustum YM
Oncogene; 2006 Apr; 25(17):2509-19. PubMed ID: 16518418
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
Azrak RG; Cao S; Pendyala L; Durrani FA; Fakih M; Combs GF; Prey J; Smith PF; Rustum YM
Biochem Pharmacol; 2007 May; 73(9):1280-7. PubMed ID: 17239826
[TBL] [Abstract][Full Text] [Related]
8. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.
Bhattacharya A; Seshadri M; Oven SD; Tóth K; Vaughan MM; Rustum YM
Clin Cancer Res; 2008 Jun; 14(12):3926-32. PubMed ID: 18559614
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
Guo B; Cao S; Tóth K; Azrak RG; Rustum YM
Clin Cancer Res; 2000 Feb; 6(2):718-24. PubMed ID: 10690558
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor activity of capecitabine in combination with irinotecan.
Cao S; Durrani FA; Rustum YM
Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
[TBL] [Abstract][Full Text] [Related]
11. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
Fakih M; Cao S; Durrani FA; Rustum YM
Clin Colorectal Cancer; 2005 Jul; 5(2):132-5. PubMed ID: 16098255
[TBL] [Abstract][Full Text] [Related]
12. Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
Azrak RG; Cao S; Durrani FA; Toth K; Bhattacharya A; Rustum YM
Cancer Lett; 2011 Dec; 311(2):219-29. PubMed ID: 21872389
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Azrak RG; Cao S; Slocum HK; Tóth K; Durrani FA; Yin MB; Pendyala L; Zhang W; McLeod HL; Rustum YM
Clin Cancer Res; 2004 Feb; 10(3):1121-9. PubMed ID: 14871992
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status.
Masunaga S; Ono K; Takahashi A; Ohnishi K; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Nagasawa H; Uto Y; Hori H
Cancer Sci; 2003 Jan; 94(1):125-33. PubMed ID: 12708486
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.
Bhattacharya A; Tóth K; Sen A; Seshadri M; Cao S; Durrani FA; Faber E; Repasky EA; Rustum YM
Clin Colorectal Cancer; 2009 Jul; 8(3):155-62. PubMed ID: 19632930
[TBL] [Abstract][Full Text] [Related]
16. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
Cao S; Durrani FA; Tóth K; Rustum YM
Br J Cancer; 2014 Apr; 110(7):1733-43. PubMed ID: 24619073
[TBL] [Abstract][Full Text] [Related]
17. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
[TBL] [Abstract][Full Text] [Related]
19. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
Dorie MJ; Kovacs MS; Gabalski EC; Adam M; Le QT; Bloch DA; Pinto HA; Terris DJ; Brown JM
Neoplasia; 1999 Nov; 1(5):461-7. PubMed ID: 10933062
[TBL] [Abstract][Full Text] [Related]
20. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
